Business Context and Reporting Period
Company: Alnylam Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 6, 2017
Event: Regulation FD Disclosure regarding a company overview presented at the Jefferies 2017 Healthcare Conference.
Key Financial Metrics
This filing does not report historical revenue, profit, cash flow, margins, or debt figures. The primary financial disclosure is an update to liquidity guidance:
- Cash Guidance Update: The Company expects to end the fiscal year 2017 with over $1.0 billion in cash, cash equivalents, fixed income marketable securities, and restricted investments.
Material Changes
The filing represents a material change to the Company's previously communicated financial outlook regarding year-end liquidity for 2017. No other material changes to operations or financial results are detailed in this specific report.
Guidance, Outlook, and Risks
Management Commentary: Management updated its cash position guidance during the Jefferies 2017 Healthcare Conference presentation.
Legal Disclaimer: The information provided in Item 7.01 is furnished and not deemed "filed" under Section 18 of the Exchange Act, nor is it incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the exact composition of the "$1.0 billion" figure (cash vs. restricted investments vs. marketable securities) in the Company's most recent 10-Q or 10-K.
- Review the full transcript or slide deck from the Jefferies 2017 Healthcare Conference for additional context on the cash burn rate or capital allocation strategy.
- Confirm if this guidance supersedes any prior public statements made in previous quarterly reports.